Medscape is available in 5 Language Editions – Choose your Edition here.


Degos Disease

  • Author: Noah S Scheinfeld, JD, MD, FAAD; Chief Editor: Dirk M Elston, MD  more...
Updated: Jan 25, 2016


In 1941, in an article entitled "Multiple Hautrekrosen bei Thromboangiitis obliterans," Kohlmeier described a case of a disease that has now been termed malignant atrophic papulosis (MAP) or Degos disease (DD). Degos recognized it as a distinct clinical entity in 1942.

Research suggests that Degos disease is a genetic disease of complement or some other clotting factor or system.[1] This is supported by the fact that eculizumab, a C5 blocker, can effectively treat systemic Degos disease.

Broadly speaking, Degos disease is a vasculopathy or an endovasculitis. It is an occlusive arteriopathy involving small-caliber vessels. Specifically, it is a progressive, small- and medium-size arterial occluding disease, leading to tissue infarction and initially involving the skin. Degos disease occurs both in a limited benign, cutaneous form and in a potentially lethal multiorgan, systemic variant.[2]

In the skin, Degos disease initially manifests with erythematous, pink or red papules. These papules heal to leave scars with pathognomonic, central, porcelain white atrophic centers. These papules usually have a peripheral telangiectatic rim.

In the systemic variant of Degos disease, the gastrointestinal tract is affected in 50% of cases. Intestinal perforation is the most severe complication and the most common cause of death in systemic Degos disease.[3] Other systems can also be involved; approximately 20% of cases of systemic Degos disease involve the CNS. Systemic manifestations usually develop from weeks to years after the onset of skin lesions, or, in rare instances, they may precede the skin lesions.

Because of the broad overlap in clinical and histological findings, High et al[4] contended in 2004 that Degos disease may not be a specific entity but, rather, may represent a common end point to a variety of vascular insults, many of which have not been fully elucidated. In 2003, Ball et al[5] proposed that Degos disease is just a variant of lupus.

Unlike lupus, (1) Degos disease does not involve the face, (2) it does not respond to therapies such as corticosteroids that at least abate lupus, (3) it does not manifest with photosensitivity, (4) viral inclusions are present in some cells in patients with Degos disease, and (5) systemic Degos disease is universally fatal, usually within 1-2 years, whereas lupus (even if severe) takes years to be fatal.[6]

Wilson et al[7] reiterated that malignant atrophic papulosis/Degos disease has both a (1) limited, cutaneous type and a (2) systemic, fatal variant.

Guhl has noted a case of Wegener granulomatosis that manifested with multiple whitish papules, perhaps similar to those in Degos disease.[8]



The etiology and the pathophysiology of Degos disease are unknown. Some have classified Degos disease as a vasculitis, a mucinosis, or a thrombotic disorder. In most cases, no circulating immune complexes, antiendothelial cell antibodies, or anticardiolipin antibodies are isolated. Although, in some cases, antiphospholipid antibodies of uncertain significance are identified. A source of confusion exists in understanding atrophic papulosis. It is likely that the differences in blood vessels in each area of the body (eg, skin, brain, intestines) help explain the different phenotypes of disease.

Some authorities suggest that Degos disease involves a primary endothelial cell defect with secondary thrombosis, leading to infarctive changes. No evidence exists supporting specific antibody-mediated damage. Additionally, medications and toxic chemicals do not appear to induce Degos disease.

The actual physical damage to blood vessels involves, at least in part, impaired fibrinolytic activity and alterations in platelet function. Classifying Degos disease as a vasculitis may not be appropriate because inflammation of the vessel walls is minimal and because immune complexes have not been found in the vessel walls.

Three possible mechanisms for this pathology have been suggested: disturbance in immunity, viral infection, and abnormality in the clotting system of blood.

In familial cases, an autosomal dominant mode of inheritance has been suggested, but this is uncertain.

In molecular analysis of cases of Degos disease with only cutaneous lesions, no paramyxovirus was identified by polymerase chain reaction.

The effectiveness of eculizumab at treating Degos disease must transform our understanding of the disease. As eculizumab is a hematological drug that blocks complement component 5 (C5), Degos disease may, in fact, be a hematological/endothelial/clotting disease that involves C5 in some pathological cascade. Degos disease thus is not a disease of immunity and should not be considered as a vasculitis. A genetic defect that parallels that of paroxysmal nocturnal hemoglobinuria (PNH) would not be surprising. Scheinfeld has discussed this concept at length.[9]

Support for the idea that Degos disease is an genetic defect of the endothelial tissue (with or with out a viral trigger) comes from Passarini who noted that in a patient suffering from systemic Degos disease who received an organ transplant, who died, on autopsy did not have any Degos disease–like changes in the transplanted tissue.[10]

A report from Japan published in 2013 investigated the expression of stromal cell–derived factor (SDF)-1/CXCL12 in Degos disease. Bone marrow stromal and endothelial cells secrete SDF-1/CXCL12. SDF-1/CXCL12 activates megakaryocyte precursors. SDF-1/CXCL12 co-stimulates platelet activation. The study compared 2 patients with Degos disease, 1 patient with cryoglobulinemia, 1 patient with antiphospholipid syndrome, and 2 healthy controls. No staining was noted in the antiphospholipid syndrome, cryoglobulinemia, or control subjects. In the Degos disease patients, investigators saw intense SDF-1/CXCL12 staining infiltrating inflammatory cells. These cells were located in the perivascular, intravascular, and perineural tissue. This finding supports the theory that Degos disease is perhaps, in part, an endothelial disease.[11]




Degos disease is rare. About 200 cases have been reported in the world literature.


Some state that Degos disease generally occurs in white young adults. However, Degos disease is reported in blacks in Africa, Arabs in Jordan,[12] Asians in Japan, and elsewhere. Any racial link is uncertain.


In 1997, Katz et al[13] noted that the disorder usually occurs in young adults, and the male-to-female ratio is approximately 3:1.

Wilson et al[7] reviewed benign cutaneous malignant atrophic papulosis in 34 men and women (30 adults and 4 kids) and noted that benign malignant atrophic papulosis is more commonly reported in women, at a female-to-male ratio of 3:1.


All ages are affected. The fatal systemic variant of Degos disease can occur in children. In 1999, Lankisch et al[14] described a 16-year-old white adolescent girl with acute abdominal pain due to visceral involvement of Degos disease that required extensive small-bowel resection. The skin manifestations had been present for 2 years before the correct diagnosis was made. She died as a result of CNS involvement from Degos disease.

Jalil et al[15] described a case in a 2-year-old child who presented with chronic abdominal pain of uncertain origin.

The benign cutaneous variant of Degos disease can occur in adults. Wilson et al[7] looked at 34 patients with benign cutaneous malignant atrophic papulosis and found their average age was 37.6 years. In 1998, Farrell et al[16] described a case of a 44-year-old woman with Degos disease and a lupus anticoagulant who, 4 years later, was alive and without systemic involvement. Electron microscopy of the white papules demonstrated interwoven tubular structures within the endothelial cells. This was consonant with reports in previous studies of Degos disease. Farrell et al[16] thought that aspirin (300 mg/d) kept her cutaneous Degos disease in check. In 1998, Requena et al[17] described a 58-year-old homosexual man with AIDS who developed typical cutaneous lesions of malignant atrophic papulosis, with no visceral involvement detected 2 years after the diagnosis of Degos disease.

Degos disease can occur in infants. Degos disease has been reported in a 7-month-old girl who showed spontaneous aggregation of platelets. A good clinical response in this patient was obtained by treatment with aspirin and dipyridamole.[18]

Contributor Information and Disclosures

Noah S Scheinfeld, JD, MD, FAAD Assistant Clinical Professor, Department of Dermatology, Weil Cornell Medical College; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, New York Eye and Ear Infirmary; Assistant Attending Dermatologist, New York Presbyterian Hospital; Assistant Attending Dermatologist, Lenox Hill Hospital, North Shore-LIJ Health System; Private Practice

Noah S Scheinfeld, JD, MD, FAAD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Abbvie<br/>Received income in an amount equal to or greater than $250 from: Optigenex<br/>Received salary from Optigenex for employment.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Jeffrey J Miller, MD Associate Professor of Dermatology, Pennsylvania State University College of Medicine; Staff Dermatologist, Pennsylvania State Milton S Hershey Medical Center

Jeffrey J Miller, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, Society for Investigative Dermatology, Association of Professors of Dermatology, North American Hair Research Society

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Franklin Flowers, MD Department of Dermatology, Professor Emeritus Affiliate Associate Professor of Pathology, University of Florida College of Medicine

Franklin Flowers, MD is a member of the following medical societies: American College of Mohs Surgery

Disclosure: Nothing to disclose.

  1. Magro CM, Poe JC, Kim C, Shapiro L, Nuovo G, Crow MK, et al. Degos disease: a C5b-9/interferon-a-mediated endotheliopathy syndrome. Am J Clin Pathol. 2011 Apr. 135(4):599-610. [Medline].

  2. Scheinfeld N. Pairing and comparing nine diseases with Degos Disease (Malignant Atrophic Papulosis): an attempt to illustrate our understanding and direct future inquiry. Dermatol Online J. 2009 Jan 15. 15(1):10. [Medline].

  3. Beuran M, Chiotoroiu AL, Morteanu S, Chilie A, Avram M, Rosu O, et al. Köhlmeier-Degos disease (Malignant Atrophic Papulosis): a cause of recurrent multiple intestinal perforations. Chirurgia (Bucur). 2009 Nov-Dec. 6:765-72. [Medline].

  4. High WA, Aranda J, Patel SB, Cockerell CJ, Costner MI. Is Degos' disease a clinical and histological end point rather than a specific disease?. J Am Acad Dermatol. 2004 Jun. 50(6):895-9. [Medline].

  5. Ball E, Newburger A, Ackerman AB. Degos' disease: a distinctive pattern of disease, chiefly of lupus erythematosus, and not a specific disease per se. Am J Dermatopathol. 2003 Aug. 25(4):308-20. [Medline].

  6. Scheinfeld N. Degos' disease is probably a distinct entity: a review of clinical and laboratory evidence. J Am Acad Dermatol. 2005 Feb. 52(2):375-6; author reply 376-8. [Medline].

  7. Wilson J, Walling HW, Stone MS. Benign cutaneous Degos disease in a 16-year-old girl. Pediatr Dermatol. 2007 Jan-Feb. 24(1):18-24. [Medline].

  8. Guhl G, Diaz-Ley B, Delgado Y, Dauden E, Fraga J, Garcia-Diez A. Wegener's granulomatosis: a new entity in the growing differential diagnosis of Degos' disease. Clin Exp Dermatol. 2009 Jul. 34(5):e1-3. [Medline].

  9. Scheinfeld N. Commentary on 'Degos disease: a C5b-9 interferon-alpha;-mediated endotheliopathy syndrome by Magro et al: a reconsideration of Degos disease as hematologic or endothelial genetic disease. Dermatol Online J. 2011 Aug 15. 17(8):6. [Medline].

  10. Passarini B, Balestri R, D'Errico A, Pinna AD, Infusino SD. Lack of recurrence of malignant atrophic papulosis of Degos in multivisceral transplant: insights into possible pathogenesis?. J Am Acad Dermatol. 2011 Aug. 65:e49-50. [Medline].

  11. Meephansan J, Komine M, Hosoda S, et al. Possible involvement of SDF-1/CXCL12 in the pathogenesis of Degos disease. J Am Acad Dermatol. 2013 Jan. 68(1):138-43. [Medline].

  12. al-Smadi RM, Abu-Jamous F, Omeish I. Degos disease in a 24-year-old Jordanian male. East Mediterr Health J. 2000 Jan. 6(1):194-6. [Medline].

  13. Katz SK, Mudd LJ, Roenigk HH Jr. Malignant atrophic papulosis (Degos' disease) involving three generations of a family. J Am Acad Dermatol. 1997 Sep. 37(3 Pt 1):480-4. [Medline].

  14. Lankisch MR, Johst P, Scolapio JS, Fleming CR. Acute abdominal pain as a leading symptom for Degos' disease (malignant atrophic papulosis). Am J Gastroenterol. 1999 Apr. 94(4):1098-9. [Medline].

  15. Jalil J, Shafique M, Rashid Dar N. Dermatological clue to diagnosis of Degos disease in a 2-year-old with obscure chronic abdominal pain. Clin Pediatr (Phila). 2008 Mar. 47(2):180-2. [Medline].

  16. Farrell AM, Moss J, Costello C, Fearfield LA, Woodrow D, Bunker CB. Benign cutaneous Degos' disease. Br J Dermatol. 1998 Oct. 139(4):708-12. [Medline].

  17. Requena L, Farina C, Barat A. Degos disease in a patient with acquired immunodeficiency syndrome. J Am Acad Dermatol. 1998 May. 38(5 Pt 2):852-6. [Medline].

  18. Torrelo A, Sevilla J, Mediero IG, Candelas D, Zambrano A. Malignant atrophic papulosis in an infant. Br J Dermatol. 2002 May. 146(5):916-8. [Medline].

  19. Theodoridis A, Konstantinidou A, Makrantonaki E, Zouboulis CC. Malignant and benign forms of atrophic papulosis (Köhlmeier-Degos disease): systemic involvement determines the prognosis. Br J Dermatol. 2014 Jan. 170(1):110-5. [Medline].

  20. Salomon MI, Mandel EH, Gallo G. Degos' disease associated with a "spontaneous cure" of diabetes. J Am Geriatr Soc. 1971 Nov. 19(11):923-32. [Medline].

  21. Asherson RA, Cervera R. Antiphospholipid syndrome. J Invest Dermatol. 1993 Jan. 100(1):21S-27S. [Medline].

  22. Saglik E, Baykal C, Buyukbabani N, Inanc M. Malignant atrophic papulosis: endocardial involvement and positive anticardiolipin antibodies. J Eur Acad Dermatol Venereol. 2006 May. 20(5):602-3. [Medline].

  23. Fernandez-Flores A, Manjon JA, Mencia J. Diabetes mellitus and Degos disease. Bratisl Lek Listy. 2008. 109(9):414-7. [Medline].

  24. Dyrsen ME, Iwenofu OH, Nuovo G, Magro CM. Parvovirus B19-associated catastrophic endothelialitis with a Degos-like presentation. J Cutan Pathol. 2008 Oct. 35 Suppl 1:20-5. [Medline].

  25. Bogenrieder T, Kuske M, Landthaler M, Stolz W. Benign Degos' disease developing during pregnancy and followed for 10 years. Acta Derm Venereol. 2002. 82(4):284-7. [Medline].

  26. Pati S, Muley SA, Grill MF, Coons S, Walker R. Post-streptococcal vasculopathy with evolution to Degos' disease. J Neurol Sci. 2011 Jan 15. 300(1-2):157-9. [Medline].

  27. Ortiz A, Ceccato F, Albertengo A, Roverano S, Iribas J, Paira S. Degos cutaneous disease with features of connective tissue disease. J Clin Rheumatol. 2010 Apr. 16(3):132-4. [Medline].

  28. Notash AY, Mazoochy H, Mirshams M, Nikoo A. Lethal systemic Degos disease with prominent cardio-pulmonary involvement. Saudi Med J. 2008 Jan. 29(1):133-7. [Medline].

  29. Tan WP, Chio MT, Ng SK. Generalized red papules with gastrointestinal complications. Diagnosis: malignant atrophic papulosis (Degos' disease). Clin Exp Dermatol. 2007 Sep. 32(5):615-6. [Medline].

  30. Egan R, Lessell S. Posterior subcapsular cataract in Degos disease. Am J Ophthalmol. 2000 Jun. 129(6):806-7. [Medline].

  31. Matsuura F, Makino K, Fukushima T, et al. Optic nerve and spinal cord manifestations of malignant atrophic papulosis (Degos disease). J Neurol Neurosurg Psychiatry. 2006 Feb. 77(2):260-2. [Medline].

  32. Sibillat M, Avril MF, Charpentier P, Offret H, Bloch-Michel E. [Malignant atrophic papulosis (Degos' disease): clinical review. Apropos of a case]. J Fr Ophtalmol. 1986. 9(4):299-304. [Medline].

  33. Subbiah P, Wijdicks E, Muenter M, Carter J, Connolly S. Skin lesion with a fatal neurologic outcome (Degos' disease). Neurology. 1996 Mar. 46(3):636-40. [Medline].

  34. Magro CM, Toledo-Garcia A, Pala O, Momtahen S, Shapiro L. Opioid associated intravenous and cutaneous microvascular drug abuse (skin-popping) masquerading as Degos disease (malignant atrophic papulosis) with multiorgan involvement. Dermatol Online J. 2015 Sep 17. 21 (9):[Medline].

  35. Hohwy T, Jensen MG, Tottrup A, Steiniche T, Fogh K. A fatal case of malignant atrophic papulosis (Degos' disease) in a man with factor V Leinden mutation and lupus anticoagulant. Acta Derm Venereol. 2006. 86(3):245-7. [Medline].

  36. Yoshikawa H, Maruta T, Yokoji H, Takamori M, Yachie A, Torii Y. Degos' disease: radiological and immunological aspects. Acta Neurol Scand. 1996 Nov. 94(5):353-6. [Medline].

  37. Amaravadi RR, Tran TM, Altman R, Scheirey CD. Small bowel infarcts in Degos disease. Abdom Imaging. 2008 Mar-Apr. 33(2):196-9. [Medline].

  38. Toledo AE, Shapiro LS, Farrell JF, Magro CM, Polito J. Laparoscopy shows superiority over endoscopy for early detection of malignant atrophic papulosis gastrointestinal complications: a case report and review of literature. BMC Gastroenterol. 2015 Nov 2. 15:156. [Medline].

  39. Scheinfeld N. Malignant atrophic papulosis. Clin Exp Dermatol. 2007 Sep. 32(5):483-7. [Medline].

  40. Zhu KJ, Zhou Q, Lin AH, Lu ZM, Cheng H. The use of intravenous immunoglobulin in cutaneous and recurrent perforating intestinal Degos disease (malignant atrophic papulosis). Br J Dermatol. 2007 Jul. 157(1):206-7. [Medline].

  41. Burgin S, Stone JH, Shenoy-Bhangle AS, McGuone D. Case records of the Massachusetts General Hospital. Case 18-2014. A 32-Year-old man with a rash, myalgia, and weakness. N Engl J Med. 2014 Jun 12. 370(24):2327-37. [Medline].

  42. Shapiro L, Whelan P, Magro C. Case 18-2014: A man with a rash, myalgia, and weakness. N Engl J Med. 2014 Oct 2. 371(14):1361. [Medline].

  43. Magro CM, Wang X, Garrett-Bakelman F, Laurence J, Shapiro LS, DeSancho MT. The effects of Eculizumab on the pathology of malignant atrophic papulosis. Orphanet J Rare Dis. 2013 Nov 26. 8:185. [Medline]. [Full Text].

  44. Shapiro LS, Toledo-Garcia AE, Farrell JF. Effective treatment of malignant atrophic papulosis (Köhlmeier-Degos disease) with treprostinil--early experience. Orphanet J Rare Dis. 2013 Apr 4. 8:52. [Medline]. [Full Text].

  45. Magro C, Shapiro L, Johnson B, Salmon J, Whelan P. Rheumatology Grand Rounds Hospital for Special Surgery (New York City) Degos Disease. Feb 10, 2010. In press.

  46. Theodoridis A, Makrantonaki E, Zouboulis CC. Malignant atrophic papulosis (Kohlmeier-Degos disease) - A review. Orphanet J Rare Dis. 2013 Jan 14. 8(1):10. [Medline].

  47. Shapiro LS, Toledo-Garcia AE, Farrell JF. Effective treatment of malignant atrophic papulosis (Kohlmeier-Degos disease) with treprostinil -- early experience. Orphanet J Rare Dis. 2013 Apr 4. 8(1):52. [Medline].

  48. Ali YN, Hamed M, Azita N. Lethal systemic degos disease with prominent cardio-pulmonary involvement. Indian J Dermatol. 2011 Sep-Oct. 56(5):564-7. [Medline]. [Full Text].

  49. Rajesh R, Basu A, Sistla SC, Jagdish S, Thappa DM, Badhe BA. Degos' disease: acute abdomen with skin rash. Indian J Gastroenterol. 2006 Jul-Aug. 25(4):187. [Medline].

  50. Kim DW, Kang SB, Lee KH, Choe GY, Park SY, Nicholay M. Degos' disease (malignant atrophic papulosis) as a fatal cause of acute abdomen: report of a case. Surg Today. 2008. 38(9):866-70. [Medline].

Four papules of Degos disease located on upper-inner arm in different stages of evolution. Courtesy of David F. Butler, MD.
Papule of Degos disease with central sclerosis and telangiectasia. Courtesy of David F. Butler, MD.
Superficial and mid-dermal perivascular lymphocytic infiltrate with focal vacuolar change at the dermoepidermal junction (hematoxylin and eosin, X100). Courtesy of David F. Butler, MD.
Alcian blue stain for mucin (X100). Courtesy of David F. Butler, MD.
Wedge-shaped area of dermal sclerosis (hematoxylin and eosin, X100). Courtesy of David F. Butler, MD.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.